SG Blocks Joint Venture Partnership Clarity Mobile Ventures Signs Agreement to Provide Coronavirus Tests For Passengers and Employees at Los Angeles International Airport (LAX)

SG Blocks, Inc. (NASDAQ: SGBX) ("SG Blocks" or the "Company"), a leading designer, innovator and fabricator of container-based structures, announced today that its Clarity Mobile Venture ("CMV") partnership with Clarity Lab Solutions has signed an agreement with the City of Los Angeles to provide a full-service modular COVID-19 laboratory and testing facility onsite at Los Angeles International Airport (LAX). The facility will be located across from Terminal 6 and is expected to open in early December 2020. At this facility, PCR tests will be administered with results available within 3 hours for passengers and airline crew, and no later than 24 hours for airport employees. Additionally, other rapid coronavirus tests including antigen tests will be provided.

"We're very pleased to announce that we have signed a definitive agreement with the City of Los Angeles to provide rapid testing to all passengers and employees at LAX to help reduce the spread of COVID-19. We believe that providing this key service at one of the nation's largest domestic and international airports will help travelers feel comfortable again," stated Paul Galvin, Chairman and CEO of SG Blocks. "We are very proud that SG Blocks is able to respond to this significant public health need as the travel industry looks to recover."

"We believe a full-service modular testing and collection site at LAX can be a model for airports and other transportation providers around the world who seek a near term solution to enhance passenger and employee safety and peace of mind during the COVID-19 pandemic," noted Andrew Whalley, Chairman with Grimshaw Architects.

The test site, created in partnership by SG Blocks and Grimshaw Architects, will utilize the SG Blocks D-Tec 2 Testing Pods. Clarity Mobile Ventures will be the primary operator of the facility and will deploy the GeneFindertm test for COVID-19, produced by OSANG Healthcare Co., Ltd, a South Korea-based global manufacturer and distributor of medical-grade diagnostic tests and equipment.

The facility will have the capacity for 1,000 PCR tests per eight-hour shift in its current capacity. Both COVID-19 RT-PCR tests as well as rapid Antigen tests will be available. The testing site will be a five-minute walk from the main terminal at LAX.

About SG Blocks, Inc.

SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteeltm, the structural core and shell of an SG Blocks building, and then customized to client specifications. For more information, visit www.sgblocks.com.

Safe Harbor Statement

Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding opening the testing facility in early December 2020 and our site at LAX being a model for airports and other transportation providers around the world who seek a near term solution to enhance passenger and employee safety and peace of mind during the COVID-19 pandemic. While SG Blocks believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to construct, deliver and deploy the modular laboratory at LAX planned, the Company's ability to position itself for future profitability, the Company's ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.